- Home
- BLNK vs AVIR Comparison
BLNK vs AVIR Comparison
Compare BLNK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | AVIR |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLNK | AVIR |
|---|---|---|
| Price | $0.65 | $3.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | $2.13 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 7.8M | 381.1K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $106,631,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $2.46 |
| 52 Week High | $2.65 | $4.02 |
Technical Indicators
Market Signals| Indicator | BLNK | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 22.25 | 63.71 |
| Support Level | $0.77 | $3.11 |
| Resistance Level | $0.85 | $3.72 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 4.35 | 71.54 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).